News
Public · Published
AQST: Anaphylm advances toward a March 2027 FDA decision as Q3 revenue falls 41% YoY
Aquestive Therapeutic said the FDA accepted Anaphylm's Class 2 resubmission, setting a March 16, 2027 PDUFA goal date for a decision. Commercial preparations and international filings are advancing. Third-quarter revenue fell 41% year over year, which the summary attributes to Suboxone order timing, while full-year 2026 guidance was maintained.
Published:
Updated:
What happened
Aquestive Therapeutic said the FDA accepted Anaphylm’s Class 2 resubmission, setting a March 16, 2027 PDUFA goal date for a decision. Commercial preparations and international filings are advancing. Third-quarter revenue fell 41% year over year, which the summary attributes to Suboxone order timing, while full-year 2026 guidance was maintained.
Confirmed
Global impact / market context
Anaphylm’s FDA decision is a future regulatory milestone: approval could allow the company to sell the product, while a delay or rejection could postpone sales. Meanwhile, the revenue decline tied to Suboxone order timing shows that sales can fluctuate with customer purchasing patterns, even as guidance remains unchanged.
Analyst inference
The supplied information presents two different time horizons: a potential future product decision in March 2027 and weaker revenue in the latest quarter. Maintained 2026 guidance indicates the company has not changed its full-year outlook in this update, but no forecast figures are provided.
Analyst inference
What to watch
- Watch for the FDA’s decision by the March 16, 2027 PDUFA goal date; the outcome would determine whether Anaphylm can move toward commercial sales. Confirmed
- Track whether commercial preparations and international filings continue to advance, since delays could push back the timing of potential product availability and related spending. Analyst inference
- Compare later revenue reports with the company’s maintained 2026 guidance to see whether Suboxone order timing continues to weigh on sales or reverses. Analyst inference
Evidence
- Original source link unavailable